(12) International Application Status Report

Received at International Bureau: 19 August 2015 (19.08.2015)

Information valid as of: 27 August 2015 (27.08.2015)

Report generated on: 14 November 2019 (14.11.2019)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2016/02032411 February 2016 (11.02.2016) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/EP2015/06782203 August 2015 (03.08.2015) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
14180255.3 (EP)07 August 2014 (07.08.2014) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
C07D 213/40 (2006.01)

(71) Applicant(s):
BASF SE [DE/DE]; 67056 Ludwigshafen (DE) (for all designated states)

(72) Inventor(s):
VIERTELHAUS, Martin; Niederfeldstrasse 54 68119 Mannheim (DE)
CHIODO, Tiziana; B4 3 68159 Mannheim (DE)
SALVADOR, Beate; Trifelsring 9 67158 Ellerstadt (DE)
VOSSEN, Marcus; Wachenheimer Strasse 8 67117 Limburgerhof (DE)
HAFNER, Andreas; Balkenweg 23 CH-4460 Gelterkinden (CH)
HINTERMANN, Tobias; Rauracherstrase 4 CH-4106 Therwil (CH)
WEISHAAR, Walter; Ludwig-Maier-Str.2 67269 Grünstadt (DE)
HELLMANN, Rolf; Kehrstr. 12A 67363 Lustadt (DE)

(74) Agent(s):
UPSCHULTE, Manfred; BASF Schweiz AG - IP Department - P.O. Box 4002 Basel (CH)

(54) Title (EN): MULTI-COMPONENT CRYSTALS OF VISMODEGIB AND SELECTED CO-CRYSTAL FORMERS OR SOLVENTS
(54) Title (FR): CRISTAUX MULTICOMPOSANTS DE VISMODEGIB ET AGENTS DE FORMATION DE CO-CRISTAUX OU SOLVANTS SÉLECTIONNÉS

(57) Abstract:
(EN): The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and sol-vents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.
(FR): L'invention concerne principalement des cristaux multicomposants comprenant un composé de formule 1 et un second composé choisi dans le groupe constitué d'agents de formation de co-cristaux et de solvants. Elle concerne également des compositions pharmaceutiques contenant lesdits cristaux multicomposants. Elle concerne en outre des méthodes de préparation desdits cristaux multicomposants. L'invention concerne aussi plusieurs aspects d'utilisation desdits cristaux multicomposants ou de compositions pharmaceutiques pour traiter une maladie.

International search report:
Received at International Bureau: 28 September 2015 (28.09.2015) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM